<DOC>
	<DOC>NCT02156466</DOC>
	<brief_summary>This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple subcutaneous ascending doses of MSB0010841 (Anti-interleukin-17A/F [Anti-IL-17A/F] Nanobody).</brief_summary>
	<brief_title>Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Chronic plaque psoriasis for at least 6 months before screening Greater than or equal to (&gt;=) 10% of BSA with plaques Psoriasis Area and Severity Index (PASI) &gt;=12 Static Physician's Global Assessment (sPGA) &gt;=3 (where scores range from 0 [clear of disease] to 5 [severe disease]) at the screening and baseline visits Other protocol defined inclusion criteria could apply Any condition, including protocolspecified laboratory findings and findings in the medical history or in the pretrial assessments which in the Investigator's opinion constitutes a risk or a contraindication for the subject's participation in the trial or that could interfere with the trial objectives, conduct or evaluation Currently having a form of nonplaque psoriasis as specified in the protocol Drug induced psoriasis Biological treatments as specified in the protocol, within 3 months prior to Day 1 Systemic immunosuppressants or phototherapy as specified in the protocol, within 1 month prior to Day 1 Use of anticoagulant medications and/or antiplatelet medications as defined in the protocol Use of aspirin as defined in the protocol Topical corticosteroid treatments other than lowstrength or lowermid strength corticosteroids on the face, scalp, axillae, and/or groin within 1 month prior to Day 1 Any previous treatment with an agent targeting interleukin (IL)17, IL12 and/or IL23 as specified in the protocol Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>MSB0010841</keyword>
	<keyword>Anti-IL17A/F Nanobody</keyword>
	<keyword>M1095</keyword>
</DOC>